Shattuck Labs, Inc.
Cena
Kam smerujú tržby
Načítavam tok výkazu ziskov a strát…
Odkiaľ plynú tržby
Fundamenty
Načítavam kľúčové čísla…
Insideri, analytici a ľudia
Všetky obchody a zmenyNačítavam insiderov, analytikov a názory…
Co se právě děje
AI souhrnO spoločnosti
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Český popis pripravujeme.
- Zamestnanci
- 40
- Krajina
- USA
- Koniec fiškálneho roka
- 31. 12.
- Dáta od
- 9. 10. 2020